Vertex's ViroChem acquisition rises to $391 million
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals has completed its acquisition of privately held ViroChem Pharma. ViroChem shareholders received $100 million in cash and around 10.7 million shares of Vertex common stock.